Z79.4

Short Definition

Long term (current) use of insulin — documents that a patient is currently on an ongoing insulin therapy regimen for management of a chronic condition, most commonly diabetes mellitus

Long Definition

ICD-10-CM code Z79.4 is a supplementary status code used exclusively as a secondary or additional code to document that a patient is currently receiving long-term insulin therapy for the management of a chronic condition, most commonly diabetes mellitus (Types 1, 2, gestational, or other specified types). This code belongs to Chapter 21 (Factors Influencing Health Status and Contact with Health Services), which contains Z-codes that describe circumstances and factors affecting a patient’s health status rather than representing diseases or injuries themselves, meaning Z79.4 can never stand alone as a primary or principal diagnosis and must always be assigned in conjunction with the primary diagnosis code that establishes the medical condition requiring insulin therapy. The fundamental purpose of Z79.4 is to communicate important clinical information about a patient’s current medication regimen that directly impacts their medical management, risk stratification, treatment planning, care coordination, surgical preparation, anesthesia considerations, hospitalization management, and quality-of-care metrics, all of which require knowledge that the patient is on insulin therapy.

The clinical significance of documenting long-term insulin use cannot be overstated: insulin is a high-alert medication associated with hypoglycemia risk, requires careful monitoring during hospitalizations and surgical procedures, necessitates dose adjustments during illness or dietary changes, interacts significantly with numerous other medications, requires patient education for self-administration and glucose monitoring, and signals a level of disease severity or progression in type 2 diabetes patients that has moved beyond oral medication management alone. The definition of “long-term” use is intentionally flexible in ICD-10-CM coding guidelines, with no specific minimum duration requirement defined; the key concept is that the patient is on insulin for an ongoing chronic condition as opposed to short-term temporary insulin use such as insulin given briefly during hospitalization to manage hyperglycemia in a patient who is not an outpatient insulin user, insulin given temporarily during pregnancy in a gestational diabetic who does not normally use insulin, or sliding-scale insulin ordered during a hospital stay for a diabetic patient whose home regimen does not include insulin.

The application of Z79.4 varies by diabetes type in important and nuanced ways established by ICD-10-CM coding guidelines and updated through annual guideline revisions: for Type 2 diabetes mellitus (E11.-), Z79.4 is clearly and consistently required as an additional code whenever the patient uses insulin as part of their diabetes management, whether insulin alone or in combination with oral hypoglycemics or other injectable non-insulin agents, because insulin use is not an inherent or assumed component of type 2 diabetes management (type 2 diabetics may be managed with diet alone, oral medications, non-insulin injectables, or insulin, and the medication regimen must be specified); for Type 1 diabetes mellitus (E10.-), the situation has been subject to evolving guideline interpretation, with the historical position being that Z79.4 is NOT required because insulin dependence is inherent to type 1 diabetes (all type 1 diabetics require insulin to survive, making the code redundant), though the 2024 ICD-10-CM Official Guidelines removed some of the explicit language clarifying this exemption, creating uncertainty among coders, with most authoritative sources and expert coders currently maintaining that Z79.4 remains unnecessary for E10.- codes because insulin use is intrinsic to the condition, though individual payer policies and facility guidelines may vary; for gestational diabetes mellitus (O24.4-), Z79.4 is required as an additional code when the gestational diabetic patient is using insulin, providing critical information about pregnancy management; for drug or chemical induced diabetes (E09.-), other specified diabetes (E13.-), and diabetes due to underlying condition (E08.-), Z79.4 should be added when insulin is part of the treatment regimen.

The specific clinical scenarios requiring Z79.4 include: patients with type 2 diabetes who were previously managed with oral medications but have transitioned to insulin (either due to pancreatic beta cell exhaustion, treatment failure, or clinical preference); type 2 diabetics on combination therapy with insulin plus oral medications (Z79.4 AND Z79.84 may both be coded when both insulin and oral hypoglycemics are actively prescribed, per guideline clarifications); type 2 diabetics on insulin plus injectable non-insulin antidiabetic drugs such as GLP-1 receptor agonists like semaglutide or liraglutide (Z79.4 AND Z79.899 should both be coded); gestational diabetics requiring insulin; patients with steroid-induced diabetes on insulin; patients with post-pancreatectomy diabetes (E13.-) on insulin; and patients with other secondary forms of diabetes requiring insulin. Conversely, Z79.4 should NOT be used when: insulin is given temporarily during hospitalization without reflecting the patient’s outpatient regimen; the patient uses oral hypoglycemics or non-insulin injectables only (use Z79.84 or Z79.85 instead); the patient has type 1 diabetes where insulin dependence is understood; or when only the physician documents insulin use during an encounter without indicating this represents the patient’s long-term ongoing regimen.

The distinction between insulin types does not affect Z79.4 coding — whether the patient uses rapid-acting insulin analogs (lispro, aspart, glulisine), long-acting basal insulin (glargine, detemir, degludec), premixed insulin formulations, human regular insulin, or any combination thereof, the same Z79.4 code is used because ICD-10-CM does not distinguish between insulin types for this status code. Similarly, the route and method of insulin delivery does not change the Z79.4 code: subcutaneous injections with syringes or pen devices, continuous subcutaneous insulin infusion (CSII) via insulin pump, and inhaled insulin (Afrezza) all report Z79.4 to document ongoing insulin therapy. From a documentation standpoint, Z79.4 may be triggered by numerous clinical indicators in the medical record: the provider’s documentation of insulin as part of the patient’s medication list or problem list, prescription for insulin in the medication reconciliation, insulin on the patient’s home medication list during hospital admission, the physician noting the patient “takes insulin” or “is on insulin therapy” in the HPI, assessment, or plan, insulin listed in the past medical history as current treatment, documentation of insulin pump or continuous glucose monitor (CGM) use, hypoglycemia related to insulin use, or any other explicit physician documentation establishing current insulin use. Coders should never assign Z79.4 based solely on medication administration records without corresponding physician documentation, should query the physician when insulin status is unclear from documentation, and should not infer insulin use from glucose level abnormalities or glucose monitoring documentation alone.

The impact of Z79.4 on clinical care coordination is substantial: hospital admissions require medication reconciliation and insulin management protocols; surgical procedures require pre-operative insulin management plans including whether to hold or reduce insulin, glucose monitoring schedules, and management of perioperative hyperglycemia and hypoglycemia; anesthesia providers need to know about insulin use for perioperative glucose management; nutrition and pharmacy consultations may be triggered; nursing care plans must address insulin administration scheduling, hypoglycemia recognition and treatment protocols, and patient/family education; and discharge planning must include insulin supply, equipment, and education. The relationship between Z79.4 and quality measures is increasingly important: many quality programs (HEDIS, STAR ratings, PCMH) specifically track outcomes in insulin-using patients, including HbA1c control, hypoglycemia rates, and adherence, making accurate documentation of Z79.4 essential for quality reporting; additionally, clinical decision support tools and electronic health records use Z79.4 to flag patients for appropriate care protocols, medication safety alerts, and clinical reminders.

From a risk adjustment and RAF (Risk Adjustment Factor) score perspective, Z79.4 itself does not directly map to an HCC category and therefore does not add directly to a patient’s risk score; however, the underlying diabetes diagnosis codes (E11.- with appropriate manifestation codes) do map to HCC categories (HCC 19 for diabetes with complications, HCC 17/18 for other diabetes categories in V28 model), and Z79.4 provides important supporting documentation that the patient’s diabetes is advanced enough to require insulin, which may support more specific or higher-severity diabetes manifestation coding that does carry HCC value. For MS-DRG purposes in inpatient hospital settings, Z79.4 is listed as a CC (Complication/Comorbidity) for certain MS-DRG groupings, meaning its presence as a secondary diagnosis can upgrade a patient’s DRG assignment from a lower-paying “without CC/MCC” DRG to a higher-paying “with CC” DRG, making accurate documentation and coding of Z79.4 financially significant for inpatient encounters; this CC impact is particularly relevant when the principal diagnosis is from a category that has a DRG differential based on CC/MCC presence. Coding guidelines also address specific combination scenarios: when a type 2 diabetic is on BOTH oral hypoglycemics AND insulin, both Z79.4 (insulin) and Z79.84 (oral hypoglycemics) should be assigned to capture the full medication regimen; when using BOTH insulin and an injectable non-insulin antidiabetic drug (GLP-1 agonist), both Z79.4 and Z79.899 (other long-term drug therapy) should be assigned; but when using ONLY oral hypoglycemics without insulin, assign only Z79.84; and when using ONLY an injectable non-insulin antidiabetic drug without insulin, assign only Z79.85 or Z79.899 depending on the specific drug.

The code underwent refinement through the transition from ICD-9-CM (where V58.67 served as the equivalent code) to ICD-10-CM implementation in 2015, with annual guideline updates continuing to clarify its application particularly with respect to type 1 versus type 2 diabetes and the expanding landscape of antidiabetic medications. Patient safety implications of proper Z79.4 coding extend beyond billing compliance: inaccurate or missing documentation of insulin use contributes to medication errors (failure to manage insulin during NPO orders for procedures), hypoglycemia events from unrecognized home insulin regimens, inadequate glucose monitoring, suboptimal discharge planning (patient not educated about insulin management), and gaps in care coordination between inpatient and outpatient providers. Documentation best practices for supporting Z79.4 include: providers explicitly listing insulin by name and type in the medication list every encounter (not just “diabetes medications”), documenting the insulin regimen in the assessment/plan when diabetes management is addressed, noting any changes to insulin regimen, including insulin use in surgical pre-operative assessments, documenting insulin use in the HPI when it is relevant to the presenting complaint (hypoglycemia, hyperglycemia, ketoacidosis), and ensuring medication reconciliation is thorough and documented at every care transition.

Compliance considerations include: Z79.4 should only be coded from physician/provider documentation (not inferred from nursing or pharmacy records alone without supporting physician documentation); the code should be active each year during the patient’s routine visits for chronic care management since Z-codes for chronic conditions may need to be recaptured annually; payer audits may review whether Z79.4 is appropriately supported by documentation of actual insulin use versus inappropriate coding when insulin is prescribed but not being taken; and facilities should establish clear documentation and coding guidelines for when Z79.4 is to be assigned to ensure consistency across encounters and providers.

Area of Body / Clinical Context

Not an anatomical code — Z79.4 is a status/circumstance code documenting medication use.

Body Systems Affected by Insulin Therapy:

Endocrine System (Primary):

• Pancreas: Insulin replaces or supplements endogenous pancreatic beta cell insulin secretion

• Islets of Langerhans (beta cells):

  • Type 1: Beta cells destroyed (autoimmune) — exogenous insulin required to sustain life

  • Type 2: Beta cells insufficient or insulin resistant — exogenous insulin supplements inadequate secretion

• Alpha cells/Glucagon: Insulin suppresses glucagon, regulates glycogenolysis

Metabolic Effects (Multiple Systems):

• Blood glucose regulation: Facilitates cellular glucose uptake

• Liver: Suppresses hepatic gluconeogenesis and glycogenolysis

• Muscle: Promotes glucose uptake and glycogen synthesis

• Adipose tissue: Promotes glucose uptake and lipogenesis

• Protein synthesis: Anabolic effects on protein metabolism

Organs Monitored During Insulin Therapy:

• Eyes: Retinopathy surveillance (diabetic retinopathy)

• Kidneys: Nephropathy monitoring (proteinuria, GFR)

• Peripheral nerves: Neuropathy assessment (sensation, reflexes)

• Cardiovascular: Atherosclerosis, cardiac disease risk

• Feet: Peripheral vascular disease, neuropathy, wounds

Includes

Z79.4 Applies to the Following Clinical Scenarios:

Type 2 Diabetes Mellitus - PRIMARY USE CASE:

• E11.9 + Z79.4 - Type 2 DM without complications, on insulin

• E11.649 + Z79.4 - Type 2 DM with hypoglycemia, on insulin

• E11.319 + Z79.4 - Type 2 DM with unspecified diabetic retinopathy

• E11.40 + Z79.4 - Type 2 DM with diabetic neuropathy

• E11.65 + Z79.4 - Type 2 DM with hyperglycemia

• E11.22 + Z79.4 - Type 2 DM with diabetic CKD, stage 3

• Any E11.- code + Z79.4 (when insulin is part of treatment)

Gestational Diabetes Mellitus:

• O24.414 + Z79.4 - Gestational DM in pregnancy, insulin controlled

• O24.424 + Z79.4 - Gestational DM in childbirth, insulin controlled

• O24.434 + Z79.4 - Gestational DM in puerperium, insulin controlled

• Note: Some O24.4- codes already specify “insulin controlled” — Z79.4 still added per guidelines

Other Specified Diabetes (E13.-):

• E13.9 + Z79.4 - Other specified DM without complications, on insulin

• E13.649 + Z79.4 - Other specified DM with hypoglycemia, on insulin

• Any E13.- code when insulin used

Drug or Chemical Induced Diabetes (E09.-):

• E09.9 + Z79.4 - Drug-induced DM without complications, on insulin

• Any E09.- code when insulin used

• Common: Steroid-induced diabetes requiring insulin

Diabetes Due to Underlying Condition (E08.-):

• E08.9 + Z79.4 - DM due to underlying condition, on insulin

• Example: Post-pancreatectomy diabetes on insulin

Insulin Delivery Methods All Use Z79.4:

• Subcutaneous injections (syringes, insulin pens)

• Insulin pump (CSII) - Continuous Subcutaneous Insulin Infusion

  • Multiple daily injections (MDI) regimen

  • Basal-bolus regimens

• Inhaled insulin (Afrezza, technosphere insulin)

• Any combination of delivery methods

Insulin Types All Use Same Z79.4:

• Rapid-acting analogs: Lispro (Humalog), aspart (NovoLog), glulisine (Apidra)

• Short-acting: Regular (Humulin R, Novolin R)

• Intermediate-acting: NPH (Humulin N, Novolin N)

• Long-acting basal: Glargine (Lantus, Basaglar, Toujeo), detemir (Levemir), degludec (Tresiba)

• Premixed: Various combinations (70/30, 75/25)

• Concentrated: U-200, U-300, U-500

• No distinction in Z79.4 code between types

Combination Therapy Scenarios:

Insulin + Oral Hypoglycemics:

• Code BOTH:

  • Z79.4 (insulin)

  • Z79.84 (oral hypoglycemic drugs)

• Example: Patient on glargine + metformin → Z79.4 + Z79.84

Insulin + Injectable Non-Insulin (GLP-1 agonist, etc.):

• Code BOTH:

  • Z79.4 (insulin)

  • Z79.899 (other long-term drug therapy)

• Example: Patient on liraglutide + insulin glargine → Z79.4 + Z79.899

Insulin + Oral + Injectable Non-Insulin:

• Code ALL THREE:

  • Z79.4 (insulin)

  • Z79.84 (oral hypoglycemic)

  • Z79.899 (injectable non-insulin)

Excludes

Excludes1 (Cannot Be Used Together):

Z79.4 Cannot Be Used as Primary Diagnosis:

• Z79.4 is a secondary code only

• Never code Z79.4 alone without a primary condition

• Must always be used WITH a primary diagnosis code

Drug Abuse or Dependence:

• F11-F19 - Drug abuse and dependence

• Z79 codes are for therapeutic drug use, NOT abuse/dependence

• If patient abuses insulin (e.g., eating disorders, insulin manipulation), drug dependence codes would apply differently

Drug Use Complicating Pregnancy/Childbirth (Specific Excludes2):

• O99.32- - Drug use complicating pregnancy, childbirth, puerperium

• Note: Z79.4 IS appropriate for gestational diabetes on insulin (O24.4-); the exclusion applies to illicit drug use or misuse

Excludes2 (May Co-Exist, Code Separately):

Long-Term Use of Other Antidiabetic Medications:

Z79.84 - Long term (current) use of oral hypoglycemic drugs:

• NOT the same as Z79.4

• For oral diabetes medications (metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones)

• Can be coded WITH Z79.4 when patient uses both

• NOT interchangeable with Z79.4

Z79.85 - Long term (current) use of injectable non-insulin antidiabetic drugs:

• For GLP-1 receptor agonists (semaglutide/Ozempic, liraglutide/Victoza, dulaglutide/Trulicity, exenatide/Byetta)

• Also amylin mimetics (pramlintide)

• Can be coded WITH Z79.4 when patient uses both

• NOT the same as Z79.4

Z79.899 - Other long-term (current) drug therapy:

• May be used for injectable non-insulin drugs not specifically captured by Z79.85

• Can be coded WITH Z79.4

When NOT to Code Z79.4:

Temporary/Short-Term Hospital Insulin:

• Insulin given ONLY during hospitalization to manage hyperglycemia

• Patient does NOT use insulin at home

• Sliding scale insulin in a non-insulin-user

• “Not a long-term insulin user — insulin started this admission for hyperglycemia management”

• Do NOT assign Z79.4 in these scenarios

Type 1 Diabetes (E10.-) - Generally NOT Needed:

• Insulin use is inherent/assumed for Type 1

• Per most current guidelines: Z79.4 not required for E10.- codes

• Type 1 diabetics cannot survive without insulin

• Adding Z79.4 to E10.- codes considered redundant by many guidelines/payers

• Exception: Some payer-specific guidelines may still require it — verify per payer

Non-Diabetic Insulin Use:

• Rare scenario (insulinoma treatment, eating disorder)

• Would require different coding framework

Z79.4 vs. Other Drug Therapy Codes:

Code	Applies To	Notes
Z79.4	Insulin	Long-term insulin for DM
Z79.84	Oral hypoglycemics	Metformin, sulfonylureas, SGLT2i, DPP-4i
Z79.85	Injectable non-insulin	GLP-1 agonists, amylin mimetics
Z79.899	Other long-term drug therapy	Other specific medications
Z79.01	Long-term use of anticoagulants	Warfarin, heparin
Z79.02	Long-term use of antithrombotics	Aspirin (antiplatelet)
Z79.52	Long-term use of systemic steroids	Prednisone, methylprednisolone

HCC Status

Z79.4 Direct HCC Mapping: Does NOT directly map to an HCC category

Z79.4 is a status/supplementary code and does not independently map to an HCC category. However, it has significant indirect HCC importance:

Why Z79.4 Has Indirect HCC Significance:

Supports More Specific/Higher-Severity Diabetes Coding:

Note

The underlying diabetes codes that accompany Z79.4 DO map to HCC categories. Z79.4 serves as supporting evidence for coding the most appropriate, specific diabetes code:

CMS-HCC Model V28 (Current) - Diabetes HCC Categories:

HCC Category	Description	Typical Codes
HCC 37	Diabetes with Chronic Complications	E11.22 (CKD), E11.40 (neuropathy), E11.319 (retinopathy)
HCC 38	Diabetes without Complication	E11.9 (type 2, no complications)
No HCC	Z79.4 itself	Supplementary code only

Clinical Significance:

• Patient with E11.9 + Z79.4 maps to HCC 38 (diabetes without complication)

• Patient with E11.40 + Z79.4 maps to HCC 37 (diabetes with chronic complication — higher RAF)

• Z79.4 documents that diabetes is insulin-requiring, suggesting disease severity/progression

• For risk adjustment audits (RADV), Z79.4 presence supports the underlying diabetes diagnosis specificity

Why Physicians Should Document Insulin Use:

Clinical Documentation Integrity (CDI) Perspective:

• Documents disease progression (type 2 now requiring insulin = more advanced disease)

• Supports quality metrics (care of insulin-using diabetics tracked separately)

• HEDIS measures: A1C control in insulin users specifically tracked

• STAR ratings: Appropriate monitoring in insulin-using diabetic patients

Medicare Advantage (MA) Plans:

• Risk adjustment in MA plans based on HCC diagnosis coding

• Proper documentation of diabetes + manifestations (supported by Z79.4 use) ensures accurate risk adjustment

• Z79.4 alone adds no RAF points

• But properly coded diabetic complications (that Z79.4 accompanies) DO add RAF points

Key Point: While Z79.4 doesn’t directly affect the HCC score, it is clinically and compliance-important because:

1. It documents medical necessity and treatment complexity

2. It supports the concurrent diabetes codes that DO impact HCC/RAF

3. Missing Z79.4 when a patient is on insulin represents incomplete/inaccurate documentation

4. Payer audits may flag encounters where diabetes is coded without documentation of treatment modality

MS-DRG Status

MS-DRG Impact: CC (Complication/Comorbidity) for Selected DRGs

Z79.4 functions as a CC (Complication/Comorbidity) in the MS-DRG system for inpatient hospital admissions under certain groupings.

What This Means:

• When Z79.4 is present as a secondary diagnosis on an inpatient claim, it may serve as a comorbidity that shifts the DRG assignment from “without CC/MCC” to “with CC”

• This shifts to a higher-paying DRG tier

• Financial impact: Can mean hundreds to thousands of dollars more per inpatient case

POA (Present on Admission) Exempt:

• Z79.4 is POA-exempt

• Does NOT require POA indicator (Present on Admission reporting not needed)

• This simplifies coding and ensures it can always be used to support DRG assignment

DRG Impact Examples:

Example 1: Pneumonia Admission

Scenario	DRG	Typical Payment
Principal Dx: J18.9 (Pneumonia) WITHOUT Z79.4	DRG 194 (Simple Pneumonia without CC/MCC)	Lower
Principal Dx: J18.9 (Pneumonia) WITH Z79.4 as CC	DRG 193 (Simple Pneumonia with CC)	Higher
Principal Dx: J18.9 WITH MCC	DRG 192 (Simple Pneumonia with MCC)	Highest

Example 2: CHF Admission

Scenario	DRG	Impact
I50.9 (CHF) without CC/MCC	Lower-tier DRG	Base payment
I50.9 + Z79.4 (if Z79.4 serves as CC)	Higher-tier DRG	Increased payment

Important Caveat:

• Z79.4’s CC status is DRG-specific — it does not universally function as a CC for every DRG

• Whether Z79.4 serves as a CC for a specific DRG depends on the principal diagnosis and the IPPS MS-DRG grouping tables

• Some DRGs already assume diabetes/insulin use in the patient population and may not be influenced

• CDIS (Clinical Documentation Integrity Specialists) should assess CC impact on a case-by-case basis

Practical Impact for Inpatient Coding:

When Z79.4 May Impact DRG:

• Patient admitted for non-diabetes condition (pneumonia, cellulitis, UTI, post-surgical management)

• Z79.4 coded as secondary diagnosis

• No other CC/MCC present

• Z79.4 may upgrade DRG from “without CC” to “with CC”

When Z79.4 May NOT Impact DRG:

• MCC already present (Z79.4 CC unnecessary — MCC already drives highest DRG)

• Principal diagnosis DRG already incorporates diabetes (some DRGs include all diabetic comorbidities)

• Multiple other CCs already present

Bottom Line for Inpatient Coding:

• Always code Z79.4 when insulin use documented and patient is inpatient

• Even if no DRG shift occurs, it is accurate documentation

• When DRG shift does occur, it represents legitimate additional reimbursement for additional clinical complexity

wRVU Status

Not Applicable — Z79.4 is a Diagnosis Code

ICD-10 diagnosis codes do not have wRVU (Work Relative Value Unit) values. wRVUs apply only to CPT procedure codes.

Indirectly Related wRVU Considerations:

While Z79.4 itself has no wRVU, it is relevant to the following CPT codes that ARE billed alongside it:

Diabetes Management CPT Codes with wRVUs:

CPT Code	Description	Approximate wRVU
99213	Established patient, moderate complexity	1.30
99214	Established patient, moderate-high complexity	1.92
99215	Established patient, high complexity	2.80
99202-99205	New patient office visits	0.93-3.17
99211	Minimal complexity visit	0.18
99495-99496	Transitional care management	2.11-3.01
96160	Health risk assessment, patient	0.45

Diabetes-Specific Procedure Codes with wRVUs:

CPT Code	Description	Approximate wRVU
95249	Ambulatory continuous glucose monitor (CGM) - physician interp	0.46
95250	CGM; sensor placement, hookup, calibration	0.58
95251	CGM; physician analysis, interpretation	0.58
99213 + modifier	Diabetes management (complex)	Per E/M level

Insulin Pump (CSII) Management:

CPT Code	Description	Approximate wRVU
99213-99215	Insulin pump management visit	Per E/M level

Note

Diabetes management services, CGM interpretation, and insulin pump management are among the physician activities that generate wRVUs and for which Z79.4 serves as a supporting secondary diagnosis code.

Code Tree / Hierarchy

ICD-10-CM Chapter: 21 - Factors Influencing Health Status and Contact with Health Services (Z00-Z99)

Block: Z77-Z99 - Persons with Potential Health Hazards Related to Family and Personal History and Certain Conditions Influencing Health Status

Category: Z79 - Long term (current) drug therapy

Code Structure:

Chapter 21: Factors Influencing Health Status (Z00-Z99) │  
├── Z77-Z99 - Persons with potential health hazards related to history │  
│ │ │  
├── Z79 - Long term (current) drug therapy │  
│ │ │ │  
├── Z79.0 - Long term (current) use of anticoagulants and antithrombotics │  
│ │ │ ├── Z79.01 - Long term use of anticoagulants (warfarin, heparin) │  
│ │ │ └── Z79.02 - Long term use of antithrombotics/antiplatelets (aspirin) │  
│ │ │ │  
├── Z79.1 - Long term (current) use of non-steroidal anti-inflammatories (NSAIDs) │  
│ │ │  
├── Z79.2 - Long term (current) use of antibiotics │  
│ │ │  
├── Z79.3 - Long term (current) use of hormonal contraceptives │  
│ │ │  
├── **Z79.4 - Long term (current) use of insulin ◄ CURRENT CODE** │  
│ │ └── [No subdivisions - single code, no laterality or specificity] │  
│ │ │  
├── Z79.5 - Long term (current) use of steroids │  
│ │ ├── Z79.51 - Long term use of inhaled steroids │  
│ │ └── Z79.52 - Long term use of systemic steroids │  
│ │ │  
├── Z79.6 - Long term (current) immunosuppressants │  
│ │ │  
├── Z79.7 - Long term (current) use of opioid analgesics │  
│ │ │  
├── Z79.8 - Other long term (current) drug therapy │  
│ │ ├── Z79.81 - Long term use of agents affecting estrogen │  
│ │ │ ├── [[Z79.810]] - Long term use of selective estrogen receptor modulators │  
│ │ │ ├── [[Z79.811]] - Long term use of aromatase inhibitors │  
│ │ │ └── [[Z79.818]] - Long term use of other agents affecting estrogen │  
│ │ ├── Z79.82 - Long term use of aspirin (NOTE: See Z79.02) │  
│ │ ├── Z79.83 - Long term use of bisphosphonates │  
│ │ ├── **Z79.84 - Long term use of oral hypoglycemic drugs ◄ Related to Z79.4** │  
│ │ ├── **Z79.85 - Long term use of injectable non-insulin antidiabetic drugs ◄ Related** │  
│ │ ├── Z79.89 - Other long term drug therapy │  
│ │ │ ├── [[Z79.890]] - Hormone replacement therapy │  
│ │ │ ├── [[Z79.891]] - Long term use of opiate analgesic │  
│ │ │ └── **[[Z79.899]] - Other long term (current) drug therapy ◄ Related (GLP-1 combo)** │  
│ │ └── Z79.899 - Other long term drug therapy │  
│ │ │  
│ └── [Parent category ends]

Z79.4 Position in Antidiabetic Drug Therapy Tree:
├── Z79.4 - Long term (current) use of insulin ◄ Exogenous insulin (all types)
│   └── Use for: All insulin types and delivery methods
│
├── Z79.84 - Long term (current) use of oral hypoglycemic drugs
│   └── Use for: Metformin, glipizide, glyburide,
│               pioglitazone, sitagliptin, empagliflozin,
│               dapagliflozin, etc.
│
├── Z79.85 - Long term (current) use of injectable non-insulin antidiabetic drugs
│   └── Use for: GLP-1 receptor agonists
│               (semaglutide, liraglutide, dulaglutide, exenatide)
│               Amylin mimetics (pramlintide)
│
└── Z79.899 - Other long term (current) drug therapy
    └── Use for: Any injectable non-insulin antidiabetic
                not captured in Z79.85 OR when Z79.85 already used
                for combination therapy documentation

Primary Diagnosis Codes Used WITH Z79.4:
├── E08.- - Diabetes mellitus due to underlying condition
│   ├── E08.9 (+ Z79.4) - No complications
│   └── E08.6- (+ Z79.4) - With other specified complications
│
├── E09.- - Drug or chemical induced diabetes mellitus
│   ├── E09.9 (+ Z79.4) - No complications
│   └── E09.6- (+ Z79.4) - Steroid-induced diabetes on insulin
│
├── E10.- - Type 1 diabetes mellitus
│   └── Generally NO Z79.4 needed (insulin inherent to Type 1)
│       Exception: Some payer policies or 2024+ guidelines may differ
│
├── E11.- - Type 2 diabetes mellitus ◄ MOST COMMON with Z79.4
│   ├── E11.9 (+ Z79.4) - Type 2, no complications, on insulin
│   ├── E11.40 (+ Z79.4) - Type 2 with neuropathy, on insulin
│   ├── E11.319 (+ Z79.4) - Type 2 with retinopathy, on insulin
│   ├── E11.22 (+ Z79.4) - Type 2 with CKD stage 3, on insulin
│   └── [Any E11.- code when insulin used]
│
├── E13.- - Other specified diabetes mellitus
│   └── E13.9 (+ Z79.4) - Other DM on insulin
│
└── O24.4- - Gestational diabetes mellitus
    ├── O24.414 (+ Z79.4) - Gestational DM in pregnancy, insulin controlled
    └── O24.424 (+ Z79.4) - Gestational DM in childbirth, insulin controlled

Coding Examples

---

Example 1: Type 2 Diabetes on Insulin Only — Office Visit

Clinical Scenario:

• 62-year-old male

• Established patient with type 2 diabetes

• On glargine (Lantus) 20 units nightly

• No complications documented this visit

• Presenting for diabetes follow-up, A1c 8.2%

• Medications: Glargine (Lantus) insulin 20 units QHS

Documentation:
“62-year-old male with type 2 diabetes mellitus on long-term insulin therapy (glargine 20 units nightly). No current hypoglycemic episodes. HbA1c 8.2% - above goal. Adjusting glargine to 22 units nightly.”

ICD-10-CM Codes:

• Primary: E11.65 - Type 2 diabetes mellitus with hyperglycemia

• Secondary: Z79.4 - Long term (current) use of insulin

CPT Codes:

• 99214 - Established patient, moderate complexity (diabetes management, medication adjustment)

Rationale:

• E11.65 captures type 2 DM with hyperglycemia (A1c above goal = hyperglycemia documented)

• Z79.4 required because patient is type 2 on insulin (not inherently assumed as in Type 1)

• No Z79.84 (no oral hypoglycemics documented)

---

Example 2: Type 2 Diabetes on Insulin AND Oral Hypoglycemic

Clinical Scenario:

• 68-year-old female

• Type 2 diabetes

• Current medications: Metformin 1000mg BID + Insulin glargine 30 units QHS + Glipizide 5mg daily

• Diabetic peripheral neuropathy also documented

Documentation:
“Type 2 diabetes mellitus with peripheral neuropathy. Patient currently managed with metformin 1000mg BID, glipizide 5mg daily, and insulin glargine 30 units at bedtime for long-term glycemic control.”

ICD-10-CM Codes:

• Primary: E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified

• Secondary 1: Z79.4 - Long term (current) use of insulin

• Secondary 2: Z79.84 - Long term (current) use of oral hypoglycemic drugs

Rationale:

• E11.40 captures the neuropathy complication (more specific than E11.9)

• Z79.4 required: patient on insulin (glargine)

• Z79.84 required: patient ALSO on oral hypoglycemics (metformin, glipizide)

• BOTH Z79.4 AND Z79.84 coded when patient uses BOTH insulin AND oral medications

---

Example 3: Type 2 Diabetes on Insulin + GLP-1 Agonist

Clinical Scenario:

• 55-year-old male

• Type 2 diabetes with obesity

• Medications: Insulin aspart (NovoLog) TID with meals + Semaglutide (Ozempic) 1mg weekly injection

• No diabetes complications documented

Documentation:
“Type 2 DM, currently on long-term insulin aspart with meals and semaglutide 1mg weekly. No diabetic complications at this time. Good glycemic control.”

ICD-10-CM Codes:

• Primary: E11.9 - Type 2 diabetes mellitus without complications

• Secondary 1: Z79.4 - Long term (current) use of insulin

• Secondary 2: Z79.85 - Long term (current) use of injectable non-insulin antidiabetic drugs (semaglutide)

Rationale:

• E11.9: Type 2, no complications

• Z79.4: Insulin use (aspart)

• Z79.85: Injectable non-insulin antidiabetic (semaglutide = GLP-1 agonist)

• BOTH coded for combination insulin + injectable non-insulin therapy

---

Example 4: Gestational Diabetes on Insulin

Clinical Scenario:

• 28-year-old female, 32 weeks pregnant

• Gestational diabetes diagnosed at 26 weeks

• Diet and oral medications failed to control glucose

• Started on insulin: NPH 10 units QAM + Regular insulin sliding scale

• Prenatal visit

Documentation:
“Gestational diabetes mellitus, 32 weeks gestation. Patient started on insulin therapy (NPH 10 units QAM + sliding scale) due to inadequate glucose control with diet modification. Long-term insulin management during pregnancy.”

ICD-10-CM Codes:

• Primary: O24.414 - Gestational diabetes mellitus in pregnancy, insulin controlled

• Secondary 1: Z79.4 - Long term (current) use of insulin

• Secondary 2: Z34.32 - Encounter for supervision of normal pregnancy, third trimester (if routine prenatal)

Rationale:

• O24.414 is specific for gestational DM in pregnancy, insulin controlled

• Z79.4 still coded per guidelines to document the specific insulin use

• Critical for obstetric nursing care and neonatal management (risk for neonatal hypoglycemia)

---

Example 5: Inpatient Pneumonia — Z79.4 as CC Affecting DRG

Clinical Scenario:

• 70-year-old male

• Admitted for community-acquired pneumonia

• Home medications include: Glargine insulin 15 units QHS (long-term)

• No other significant comorbidities (no CHF, no COPD, no renal failure)

• POA: Z79.4 is exempt from POA reporting

Inpatient ICD-10-CM Codes:

• Principal Diagnosis: J18.9 - Pneumonia, unspecified organism

• Secondary Diagnosis: Z79.4 - Long term (current) use of insulin (CC)

• Secondary Diagnosis: E11.9 - Type 2 diabetes mellitus (home condition, continue to manage)

MS-DRG Impact:

• WITHOUT Z79.4 (or other CC/MCC): DRG 194 - Simple Pneumonia & Pleurisy without CC/MCC

• WITH Z79.4 as CC: DRG 193 - Simple Pneumonia & Pleurisy with CC

• DRG shift from 194 → 193 = increased facility payment

ICD-10-PCS Procedure (Inpatient):

• Insulin administration coded in ICD-10-PCS for inpatient:

  • 3E0F3GC - Introduction of other therapeutic substance into respiratory tract, percutaneous approach (if respiratory treatments given)

  • Insulin administration: 3E03GC or similar PCS code for subcutaneous insulin

Documentation Requirement:
“Patient on long-term home insulin therapy (Lantus 15 units nightly) for type 2 diabetes. Continue home insulin dose. Monitor blood glucose QID. Hypoglycemia protocol in place.”

---

Example 6: Surgical Pre-op Documentation — Critical Importance of Z79.4

Clinical Scenario:

• 65-year-old male scheduled for elective knee replacement

• Type 2 diabetes on insulin (glargine + lispro sliding scale)

• Preoperative assessment

Pre-op Documentation:
“Type 2 diabetes mellitus, long-term insulin user (glargine 25 units QHS + lispro sliding scale with meals per endocrinologist). Perioperative insulin management plan: Day before surgery - continue glargine 25 units. Morning of surgery - hold lispro, reduce glargine to 50% (12 units). Post-op: Resume home insulin once tolerating oral intake. Target glucose 140-180 mg/dL perioperative. Endocrinology consulted for complex insulin management.”

ICD-10-CM Codes (Pre-op Visit):

• Primary: Z01.818 - Encounter for other preprocedural examination

• Secondary 1: E11.9 - Type 2 diabetes mellitus

• Secondary 2: Z79.4 - Long term (current) use of insulin

• Secondary 3: M17.11 - Primary osteoarthritis, right knee (reason for surgery)

Why Z79.4 Critical Here:

• Anesthesia team must know patient is on insulin

• Perioperative glucose management protocol must be established

• Risk of intraoperative/postoperative hypoglycemia

• Patient education needed for perioperative medication management

• Endocrinology consult may be required

---

Example 7: Type 2 Diabetes — Temporary Hospital Insulin ONLY (Do NOT Code Z79.4)

Clinical Scenario:

• 58-year-old female

• Type 2 diabetes normally managed with metformin only

• Admitted for sepsis

• During hospital stay: Blood glucose 380 mg/dL, started on IV insulin drip

• Post-hospitalization plan: Return to metformin only

Documentation:
“Type 2 diabetes mellitus, normally on metformin only. Insulin drip started this admission for severe hyperglycemia in setting of sepsis. Will discontinue insulin upon discharge; patient NOT a long-term insulin user at home.”

INCORRECT Coding:

• Z79.4 (WRONG — patient is NOT a long-term insulin user; insulin started ONLY for this acute hospitalization)

CORRECT ICD-10-CM Codes:

• Primary: A41.9 - Sepsis, unspecified organism

• Secondary 1: E11.65 - Type 2 DM with hyperglycemia

• Secondary 2: Z79.84 - Long term (current) use of oral hypoglycemic drugs (metformin)

• Do NOT code Z79.4 — temporary hospital insulin, not long-term use

Rationale:

• Z79.4 = long-term home insulin use only

• Temporary hospital-only insulin does not qualify

• Code Z79.84 for the metformin that IS her long-term medication

• This is a critical distinction to prevent inaccurate documentation

---

Example 8: Type 1 Diabetes — Standard Position (No Z79.4 Required)

Clinical Scenario:

• 25-year-old female

• Type 1 diabetes since age 8

• On insulin pump (CSII) with continuous subcutaneous insulin infusion

• CGM (continuous glucose monitor) in use

• No complications

Documentation:
“Type 1 diabetes mellitus, managed with CSII insulin pump since age 15. Using Dexcom G7 CGM. No diabetic complications currently. A1c 7.1%. Insulin pump: basal rate 0.8 units/hour, bolus ratios 1:15 grams carb.”

CORRECT ICD-10-CM Codes:

• Primary: E10.9 - Type 1 diabetes mellitus without complications

• Secondary: Z96.41 - Presence of insulin pump (if needed to document pump)

• NO Z79.4 — Per standard guideline consensus, Z79.4 not required for Type 1 (insulin inherent to condition)

Controversial Note:

• Some payer guidelines and some interpretations of 2024 ICD-10-CM updates suggest Z79.4 SHOULD be added even for Type 1

• Best practice: Verify per your facility policy and payer-specific guidelines

• If payer specifically requires Z79.4 for Type 1 claims → add it per that payer’s policy

• Consensus among most coding experts: E10.- does NOT require Z79.4

---

Example 9: Steroid-Induced Diabetes on Insulin

Clinical Scenario:

• 55-year-old male with rheumatoid arthritis

• On long-term prednisone 20 mg daily (for RA)

• Developed steroid-induced diabetes

• Now on insulin NPH 20 units QAM to manage steroid-induced hyperglycemia

Documentation:
“Steroid-induced diabetes mellitus secondary to long-term prednisone use for rheumatoid arthritis. Now on long-term insulin NPH 20 units QAM for glucose control. Will attempt to taper prednisone; if glucose normalizes, may discontinue insulin.”

ICD-10-CM Codes:

• Primary: E09.649 - Drug or chemical induced diabetes mellitus with hypoglycemia without coma (or E09.65 with hyperglycemia as appropriate)

• Secondary 1: Z79.4 - Long term (current) use of insulin

• Secondary 2: Z79.52 - Long term (current) use of systemic steroids (prednisone)

• Secondary 3: M06.9 - Rheumatoid arthritis (underlying condition)

• Adverse effect code: T38.0X5A - Adverse effect of glucocorticoids (if documenting steroid as cause)

Note: E09.- used (not E11.-) because diabetes is drug-induced, not primary type 2

---

Example 10: Documentation Query — When to Query Physician

Clinical Scenario:

• Inpatient chart review by CDI Specialist

• Patient: 72-year-old admitted for UTI

• Medication list includes: “Insulin glargine 18 units QHS”

• Problem list: “Diabetes mellitus”

• No physician note specifying: Type 1 or Type 2? Long-term home insulin? How long on insulin?

Issue: Coder cannot confidently determine:

1. Type of diabetes (E10 vs E11)

2. Whether insulin is long-term home use or newly started

3. Whether diabetes has complications

Query to Physician:

“Dear Dr. [Name],

The patient’s medication list indicates insulin glargine 18 units QHS. To ensure accurate and complete documentation, please clarify:

1. Does this patient have Type 1 or Type 2 diabetes mellitus?

2. Is insulin glargine part of this patient’s long-term home insulin regimen (prior to this admission)?

3. Are there any diabetic complications (neuropathy, nephropathy, retinopathy, peripheral vascular disease)?

Your clarification will ensure complete and accurate documentation in the medical record.

Thank you,
CDI Specialist”

Expected Response and Coding:

• If physician confirms: “Type 2, long-term home insulin since 2019, no complications”

  • Primary: E11.9 - Type 2 DM without complications

  • Secondary: Z79.4 - Long term (current) use of insulin

• If physician confirms complications exist:

  • Primary: E11.40 (neuropathy) or E11.22 (CKD) etc.

  • Secondary: Z79.4

---

Documentation Requirements

To Support Z79.4, the Medical Record Must Contain:

1. Explicit Statement of Insulin Use:

Acceptable Documentation:

• “Patient takes insulin glargine 20 units at bedtime”

• “Long-term insulin therapy for type 2 diabetes”

• “Currently on insulin [type] for diabetes management”

• “Insulin [name] is part of patient’s home medication regimen”

• “Patient is an insulin-using diabetic”

• “Insulin-dependent type 2 diabetes mellitus”

• Medication reconciliation listing insulin as home medication

2. Documentation of Chronic/Long-Term Nature:

Indicates Long-Term:

• Insulin listed on problem list or medication list (ongoing)

• History of insulin use (“on insulin since [year]”)

• Insulin pump user (CSII)

• CGM user (continuous glucose monitoring — implies insulin use)

• Multiple insulin injections daily (MDI regimen)

• Insulin refill prescribed at visit

• Lab orders including “insulin management” protocols

3. Provider Documentation (NOT Sufficient Alone):

• Medication administration records (MAR) alone — not sufficient without physician documentation

• Nursing documentation of insulin administration alone — not sufficient without physician confirmation

• Pharmacy dispensing records alone — not sufficient

4. Types of Encounters Where Z79.4 Should Be Coded:

Encounter Type	Code Z79.4?	Notes
Routine diabetes follow-up, insulin user	YES	Document every visit
Annual wellness exam, insulin diabetic	YES	Part of problem list
Hospital admission, home insulin user	YES	Part of admission HPI/medication reconciliation
Pre-op assessment, insulin diabetic	YES	Critical for perioperative management
ER visit, insulin diabetic (any reason)	YES	If relevant to encounter
Hospital admission, insulin started this admission only	NO	Not long-term use
Patient has prescription for insulin but not currently taking	NO	Must be actively using

5. What NOT to Code Z79.4 For:

• Patient received insulin injection once in office (not long-term)

• Insulin ordered on PRN basis without regular use

• Patient “may start insulin” (future plan, not current use)

• Patient recently STOPPED using insulin (no longer long-term use)

• Insulin given during emergency/acute illness only

---

Related Codes

Complete Coding Picture for Insulin-Using Diabetic Patient:

Code	Description	Relationship to Z79.4
E11.9	Type 2 DM without complications	Primary dx — most common with Z79.4
E11.40	Type 2 DM with neuropathy	Primary dx with complications
E11.22	Type 2 DM with CKD, stage 3	Primary dx with renal complication
E11.319	Type 2 DM with diabetic retinopathy	Primary dx with eye complication
E11.649	Type 2 DM with hypoglycemia	Primary dx — common in insulin users
E11.65	Type 2 DM with hyperglycemia	Primary dx — if A1c above goal
E10.9	Type 1 DM without complications	Primary dx — generally no Z79.4 needed
O24.414	Gestational DM, insulin controlled	Primary dx with Z79.4 for insulin
Z79.84	Long-term oral hypoglycemics	May co-code WITH Z79.4
Z79.85	Injectable non-insulin antidiabetics	May co-code WITH Z79.4
Z79.899	Other long-term drug therapy	May co-code WITH Z79.4
Z96.41	Presence of insulin pump	Document if CSII pump user
Z13.1	Encounter for screening for diabetes	Screening visits
Z71.3	Dietary counseling	Nutrition management
E87.0	Hyperosmolality/hypernatremia	May co-exist with hyperglycemia
E16.0	Drug-induced hypoglycemia without coma	Insulin-induced hypoglycemia
E15	Nondiabetic hypoglycemic coma	Severe hypoglycemia
Z87.39	Personal history of other endocrine disorders	If diabetes resolved

---

Summary

Z79.4 (Long Term Current Use of Insulin) Key Points:

What It Is:

• Secondary/additional code ONLY (never primary/principal)

• Documents patient is on ongoing insulin therapy

• Status/circumstance code (not a disease)

When to Use:

• Type 2 diabetes (E11.-) on insulin — REQUIRED

• Gestational diabetes (O24.4-) on insulin — REQUIRED

• Other specified/drug-induced/condition-associated diabetes on insulin — REQUIRED

• Type 1 diabetes (E10.-) — Generally NOT required (insulin inherent)

When NOT to Use:

• As primary/principal diagnosis

• For temporary hospital-only insulin (not home regimen)

• For patients who no longer take insulin

• Without a primary diabetes or condition code

Combination Coding Rules:

• Insulin + oral hypoglycemics: Z79.4 AND Z79.84

• Insulin + injectable non-insulin (GLP-1): Z79.4 AND Z79.85

• Insulin + oral + injectable: Z79.4 + Z79.84 + Z79.85

HCC:

• Z79.4 does NOT directly map to HCC

• Supporting diabetes codes (E11.-, E10.-) DO map to HCC 37-38 (V28 model)

• Proper Z79.4 use supports complete, specific diabetes code selection which impacts HCC

MS-DRG:

• Z79.4 is a CC (Complication/Comorbidity) for certain DRGs

• Can upgrade DRG from “without CC” to “with CC” → increased inpatient payment

• POA-exempt (no Present on Admission indicator required)

wRVU:

• Not applicable (diagnosis code, not procedure code)

Documentation:

• Must be supported by physician documentation of active insulin use

• Should be coded at every encounter where patient is an active insulin user

• Cannot be inferred from MAR or pharmacy records alone

Key Distinction:

• Z79.4 = Insulin (injected or pumped)

• Z79.84 = Oral diabetes medications

• Z79.85 = Injectable non-insulin (GLP-1 agonists)

---

This comprehensive guide to Z79.4 covers all aspects of documentation, coding guidance, clinical context, HCC/DRG impact, and practical coding examples for long-term insulin use in clinical practice.